Author

A. Sanders

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Handa· 1 shared A. Mukundan· 1 shared A. P. Hinck· 1 shared A. Vora· 1 shared C. Brouwer· 1 shared C. Ciancia· 1 shared C. S. Hinck· 1 shared C. Schoenherr· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Handa

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The helminth TGF-beta mimic TGM4 is a modular ligand that binds CD44, CD49d and TGF-beta receptors to preferentially target myeloid cells

S. Singh, D. J. Smyth, K. Cunningham, A. Mukundan, C.-H. Byron, C. S. Hinck, M. P. J. White, C. Ciancia, N. Wosowska, A. Sanders, R. Jin, S. Lilla, S. Zanivan, C. Schoenherr, G. Inman, , R. M. Maizels

This paper identifies TGM4, a helminth TGF-beta mimic, as a modular ligand that selectively targets myeloid cells through specific receptor interactions, differing from TGM1's broader T cell targeting.

bioRxiv · Nov 13, 2023 · PreprintImmunology

Overexpression of MUC1 influences the anti-proliferative effect of STAT3-inhibitor Napabucasin in epithelial cancers.

M. Bose, A. Sanders, A. Handa, A. Vora, C. Brouwer, P. Mukherjee

This study shows that overexpressed MUC1 enhances the anti-proliferative effect of the STAT3 inhibitor Napabucasin in epithelial cancers.

bioRxiv · Jun 22, 2023 · PreprintCancer Biology